LIXT Lixte Biotechnology Holdings Inc.: רווח למניה ב-12 החודשים האחרונים

Lixte Biotechnology relies on outsourcing production and testing to maintain workforce flexibility. The company optimizes chemical supplies through a global network of laboratories, thereby reducing regulatory risks. Early-stage inhibitor development keeps finances aligned with R&D expenditures. On GURU.Markets, the annual growth of basic net income per share (TTM) shows that the parameter value is 22.80.

The twelve-month earnings per share (EPS) trend measures the inertia of fundamental growth, reflecting the business's ability to scale net income relative to the volume of shares outstanding. By analyzing the current EPS YoY TTM growth rate, an investor can assess how geopolitical barriers in the scientific cooperation of Lixte Biotechnology (LIXT) impact the efficiency of oncology drug development, where any deceleration in the trend signals a risk of capital freeze.